The Science
The most studied bonding
molecule in human history.
Oxytocin has been studied in over 1,000 peer-reviewed trials. The findings are consistent: it increases desire, deepens bonding, and reduces sexual distress. Here's what the data actually says.
Start Free Consultation
144%
Increase in Sexual Quality of Life
Muin et al., 2015
30 min
Time to onset via olfactory pathway
Striepens et al., 2011
503A
Licensed compounding pharmacy standard
USP <797>
5
Peer-reviewed citations on this page
Indexed journals
Research Citations
Look what this molecule does.
144%
Increase in Sexual Quality of Life
01
PEER REVIEWEDMuin et al., 2015
Fertility & Sterility
View primary source ↗A 144% improvement in sexual quality of life. In a randomized controlled trial, intranasal oxytocin also improved Female Sexual Function by 26%, Sexual Desire by 29%, and reduced Sexual Distress by 36% in women with hypoactive sexual desire disorder.
↑
Sexual Motivation & Partner Bonding
02
PEER REVIEWEDBehnia et al., 2014
Hormones and Behavior
View primary source ↗When one partner used intranasal oxytocin, both partners experienced increased sexual motivation and partner-directed bonding behavior. The effect didn't require both people to use it.
15–30 min
Onset via Olfactory Pathway
03
PEER REVIEWEDStriepens et al., 2011
Progress in Brain Research
View primary source ↗Intranasal oxytocin reaches the brain in 15–30 minutes via the olfactory pathway, with effects lasting 75–150 minutes. That's the window. That's why 30 minutes before intimacy is the protocol.
2×
Extended Mucosal Contact Time
04
INDUSTRY DATAPCCA MucoLox™ Validation
PCCA Technical Bulletin
View primary source ↗MucoLox™ extends mucosal contact time and improves bioavailability compared to standard aqueous nasal sprays. It's the same delivery vehicle used by leading compounding pharmacies for peptide nasal formulations.
503A
Licensed Compounding Pharmacy
05
INDUSTRY DATA503A Compounding Standards
USP <797>
View primary source ↗503A compounding pharmacies operate under state pharmacy board oversight and USP <797> sterile compounding standards. DEEP BREATH™ is compounded by a licensed 503A pharmacy using PCCA MucoLox™ as the delivery vehicle.
Citations are provided for educational purposes. DEEP BREATH™ is a compounded medication and has not been evaluated or approved by the FDA. Research findings do not guarantee individual outcomes. Always consult a qualified healthcare provider.
Our Standards
Built on trust.
Licensed US Clinicians
Independent providers review every intake
503A Pharmacy
USP <797> sterile compounding standards
HIPAA Compliant
Your health data is protected
HSA/FSA Eligible
Use pre-tax dollars for your prescription
Ready to Start?
The science is clear.
The next step is yours.
A licensed US clinician will review your health history and determine if DEEP BREATH™ is right for you. Free consultation. No charge until approved.
Free consultation · Takes 2 minutes · No charge until approved